Side-by-side comparison of AI visibility scores, market position, and capabilities
Williams-Sonoma's modern home furnishings brand with $2B+ revenue; Fair Trade and artisan-sourced furniture and décor at accessible-premium prices competing with Crate & Barrel and CB2.
West Elm is a modern home furnishings and décor retailer known for its contemporary, artisan-crafted aesthetic — producing furniture, bedding, lighting, and rugs at accessible-premium price points that blend modern design with Fair Trade and artisan partnerships. Founded in 2002 in Brooklyn, New York and owned by Williams-Sonoma, Inc. (NYSE: WSM), West Elm operates approximately 100 stores in the US and internationally, generating approximately $2+ billion in annual revenue. Williams-Sonoma's portfolio also includes Williams-Sonoma, Pottery Barn, Pottery Barn Kids, and Rejuvenation.\n\nWest Elm's design identity centers on handcrafted textures (woven throws, artisan ceramics, hand-knotted rugs), organic materials (FSC-certified wood, organic cotton), and a modern-meets-warm aesthetic that differentiates it from IKEA's flat-pack minimalism or Crate & Barrel's cleaner modernism. The brand's Fair Trade certification and commitment to artisan workshop sourcing (products made in places like India, Morocco, and Peru through certified fair trade suppliers) provides ethical differentiation that resonates with its core millennial homeowner demographic.\n\nIn 2025, West Elm operates within Williams-Sonoma's highly profitable home goods portfolio — Williams-Sonoma has been one of the top-performing specialty retailers, with strong direct-to-consumer digital capabilities. West Elm competes with Crate & Barrel, CB2, Pottery Barn (sibling brand), IKEA, and direct-to-consumer home brands like Article and Joybird for modern home furnishings. The 2025 strategy focuses on expanding the brand's B2B offering (West Elm Workspace for office furnishings), growing international markets, and continuing its digital-first shopping experience with augmented reality room visualization and faster delivery capabilities.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.